REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
20/07/2026
Voltar para busca
Dado oficial do USPTO
NANOPRIMER
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
32
Atualização mais recente
20/07/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42, 44
Data de depósito
24/06/2020
Data de registro
20/07/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
20/07/2021
Última transação
20/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
84
Localização do titular
FR
Examinador
SAITO, KIM
Unidade examinadora
N60
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the following: the stylized wording "NANOPRIMER" in white against a blue background.
Titulares e representantes
Titulares
NANOBIOTIX
Curadigm
Representantes
Michele S. Katz Advitam IP, LLC
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Products for medical use especially for metabolic pathways to prevent and treat acid-base imbalancemetabolic brain diseasesdisorders of calcium metabolismDNA repair-deficiency disordersglucose metabolism disordershyperlactatemiairon metabolism disorderslipid metabolism disordersmalabsorption syndromesmetabolic syndrome Xinborn error of metabolismmitochondrial diseasesphosphorus metabolism disordersporphyriasproteostasis deficienciesmetabolic skin diseaseswasting syndrome and water-electrolyte imbalance; products for medical use especially for the diagnosis and treatment of tumors; preparations for medical use especially for modifying the bioavailability of therapeutic agents; preparations for medical use especially for modifying liver functions to prevent and treat alcohol-related liver diseasenon-alcoholic fatty liver diseasehepatitishaemochromatosisprimary biliary cirrhosis and liver cancer; preparations for medical use for modifying the functions of the reticuloendothelial system to decrease reticuloendothelial system ability to trap and metabolize therapeutic agents such as nanomedicinesmonoclonal antibodiesantibody-drug conjugatessmall moleculesto prevent and treat Gaucher's diseasemastocytosishistiocytosis; preparations based on nanomaterials for the delivery of therapeutic agents combined with nucleic acidsmall moleculesproteins and peptides; nanoparticles for medical use to prevent and treat central nervous system diseasescancermetabolic diseasesinfectionimmunologic diseaseshematologic diseaserare diseasesorgan transplant rejection; chemical reagents for medical use; bacteriological preparations for medical use; biological preparations for medical use to prevent and treat central nervous system diseasescancermetabolic diseasesinfectionimmunologic diseaseshematologic diseaserare diseasesorgan transplant rejection; enzymes for medical use; enzyme preparations for medical use; diagnostic products for medical use to prevent and treat central nervous system diseasescancermetabolic diseasesinfectionimmunologic diseaseshematologic diseaserare diseasesorgan transplant rejection; drugs for medical use to prevent and treat central nervous system diseasescancermetabolic diseasesinfectionimmunologic diseaseshematologic diseaserare diseasesorgan transplant rejection; medicines for human to prevent and treat central nervous system diseasescancermetabolic diseasesinfectionimmunologic diseaseshematologic diseaserare diseasesorgan transplant rejection; tonics for medical use to prevent and treat central nervous system diseasescancermetabolic diseasesinfectionimmunologic diseaseshematologic diseaserare diseasesorgan transplant rejection; antibiotics; antiseptics; chemico-pharmaceutical preparations for the treatment of central nervous system diseasescancermetabolic diseasesinfectionimmunologic diseaseshematologic diseaserare diseasesorgan transplant rejection; pharmaceutical preparations for the treatment of central nervous system diseasescancermetabolic diseasesinfectionimmunologic diseaseshematologic diseaserare diseasesorgan transplant rejection; dietetic substances preparations adapted for medical use; remedies for human medicine for the treatment of central nervous system diseasescancermetabolic diseasesinfectionimmunologic diseaseshematologic diseaserare diseasesorgan transplant rejection
Classe 42
Scientific and technological services as well asresearch and design services particularly in the field of nanomedicine which is nanotechnology applied to medicine; biological research; research in bacteriology; conducting early evaluations in the field of new pharmaceuticals; design and development of new products for third parties; conducting clinical trials for others in the field of new pharmaceuticals; research services in the field of new pharmaceuticals; chemical analysis; chemical research; chemical engineering; chemical research and analysis services in the field of physico-chemical characterization and concept design; engineering worksurveying; research and development of new products for third parties; technical research in the field of new pharmaceuticals; radiobiology research; research in nanoscience and nanotechnologyespecially applied to medicine
Classe 44
Healthcare especially in the field of nanomedicine; medical services especially in the field of nanomedicine; hospital services; medical assistance; physiotherapy
Publicações
Histórico de despachos e eventos da marca no USPTO.
32 publicações encontradas
CHLD
CHANGE OF OWNER RECEIVED FROM IB
27/12/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
13/12/2021
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
04/12/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
17/11/2021
FIMP
FINAL DISPOSITION PROCESSED
17/11/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
20/10/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
20/07/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/05/2021
PUBO
PUBLISHED FOR OPPOSITION
04/05/2021
GPNX
NOTIFICATION PROCESSED BY IB
02/05/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
14/04/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
14/04/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
14/04/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
26/03/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
26/03/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
26/03/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
26/03/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
26/03/2021
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
26/03/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
19/01/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
18/01/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
18/01/2021
RFNT
REFUSAL PROCESSED BY IB
29/11/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/11/2020
RFRR
REFUSAL PROCESSED BY MPU
05/11/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
18/10/2020
CNRT
NON-FINAL ACTION WRITTEN
17/10/2020
DOCK
ASSIGNED TO EXAMINER
27/09/2020
MAFR
APPLICATION FILING RECEIPT MAILED
18/08/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
14/08/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
13/08/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace NANOPRIMER ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.